The clinical trial sponsored by Shanghai Tongji Hospital focuses on the use of CD19-directed CAR T cell therapy for patients with relapsed/refractory B cell malignancies, specifically targeting those who have undergone multiple chemotherapy regimens without success. The market for CAR T cell therapies is rapidly expanding, particularly in the oncology sector, with significant competition from established players like Novartis and Gilead. The trial's focus on a patient population with limited treatment options positions it favorably for potential market entry, assuming positive safety and efficacy outcomes. Diligence should consider the regulatory landscape in China and potential for global expansion, as well as the need for robust manufacturing capabilities for CAR T cell products.